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Background: Retinal degeneration is a main feature of Bardet-Biedl syndrome for which the mechanism causing photore-
ceptor cell apoptosis remains elusive.
Results: Apoptosis is caused by protein accumulation in the photoreceptor inner segment activating an unfolded protein
response.
Conclusion: Pharmacological reduction of apoptosis preserves light detection ability.
Significance: This therapeutic approach could be used to slow the degeneration and is potentially applicable to other
ciliopathies.
Ciliopathies, a class of rare genetic disorders, present often
with retinal degeneration caused by protein transport defects
between the inner segment and the outer segment of the photo-
receptors. Bardet-Biedl syndrome is one such ciliopathy, genet-
ically heterogeneous with 17 BBS genes identified to date, pre-
senting early onset retinitis pigmentosa. By investigating
BBS12-deprived retinal explants and the Bbs12/ murine
model, we show that the impaired intraciliary transport results
in protein retention in the endoplasmic reticulum. The protein
overload activates a proapoptotic unfolded protein response
leading to a specific Caspase12-mediated death of the photore-
ceptors. Having identified a therapeutic window in the early
postnatal retinal development and through optimized pharma-
cologicalmodulation of the unfolded protein response, combin-
ing three specific compounds, namely valproic acid, guanabenz,
and a specific Caspase12 inhibitor, achieved efficient photore-
ceptor protection, therebymaintaining light detection ability in
vivo.
Bardet-Biedl syndrome (BBS, OnlineMendelion Inheritance
in Man 290900)2 is characterized by early onset retinitis pig-
mentosa (RP), polydactyly, obesity, renal dysfunction, hypogo-
nadism, and cognitive impairment (1). It is an emblematic
member of the ciliopathies, a group of inherited genetic dis-
eases caused by a defect in the primary ciliumorganelle (2). BBS
is a genetically heterogeneous condition with at least 17 genes
identified so far (BBS1–BBS17) (3). The BBS proteins are local-
ized within the primary cilium-centrosome complex and are
involved in the biogenesis and/or function of the primary cil-
ium (4). Functionally, sevenBBSproteins (BBS1, 2, 4, 5, 7, 8, and
9) form a stable complex named the BBSome and are involved
in ciliary transport of specific cargo proteins (5). The BBSome
assembly is dependent of a second BBS complex, a chaperone
complex including BBS6, 10, and 12 (6). Because of the strong
functional interactions between these BBS proteins, the loss of
one of these proteins impairs the proper functioning of the
ciliary complex and leads to the disabling clinical manifesta-
tions that characterize BBS.
Retinal degeneration inBBS is thought to be due to a defect in
intraciliary transport (ICT) in the connecting ciliumof the pho-
toreceptor (7). The latter is amodified primary cilium that links
the biosynthetically active inner segment (IS) to the light-sen-
sitive outer segment (OS) (2). BBS-mediated impairment of the
ICT causes a slow process of degeneration eventually causing
the total loss of the photoreceptors (8–12). Retinal phenotyp-
ing in the reported BBS mouse models has, indeed, shown that
apoptosis correlated with an impaired ICT of major photore-
ceptor proteins like Rhodopsin and Arrestin (7). Interestingly,
it was also shown thatmutated forms of Rhodopsin accumulate
in the IS and trigger apoptosis (13), which is reminiscent of the
phenotype observed in several ciliopathies that also cause pro-
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tein overload in the IS (14). Protein accumulation is deleterious
because it stresses the endoplasmic reticulum (ER). In an
attempt to alleviate ER stress, the cell activates a series of coor-
dinated cellular responses known as the unfolded protein
response (UPR) (15). Unfortunately, when the UPR fails to
restore cellular homeostasis, the UPR switches to a proapop-
totic process. Other animal models of inherited RP are also
linked to ER stress (16), such as the rd1 mouse (17), and RP
models linked to Rhodopsin mutations (18–20). Interestingly,
therapeutic efforts to modulate the UPR in some RP models
were efficient in protecting the photoreceptors against cell
death (21, 22), but to date, none of them was able to maintain
the ability of the retina to detect light.
In an attempt to prevent photoreceptor apoptosis in BBS, we
studied the UPR signaling cascade in BBS12-deficient retinal
explants and the corresponding Bbs12 knock-outmousemodel
(Bbs12/). BBS12 inactivation impaired ICT in the photore-
ceptors and triggered an activation of the UPR caused by pro-
tein accumulation in the IS. This UPR caused activation of
Caspase12, which drove the apoptosis in the Bbs12-deprived
photoreceptors. Interestingly, through a specific pharmacolog-
ical modulation of the UPR to alleviate the ER stress, we were
able to prevent apoptosis of the photoreceptor both ex vivo and
in vivo, thereby maintaining light detection ability of the retina
in the Bbs12/mouse.
EXPERIMENTAL PROCEDURES
Retinal Explants—Wild-type animals had a C57BL/6 back-
ground. Retinal explants were cultured as previously described
(23). Briefly, 15-day-old mice were sacrificed by decapitation,
and the eyes were removed and incubated for 10min at 37 °C in
a 10% trypsin solution (catalogue number 25200-072; Invitro-
gen). Digestion was stopped by transferring the eyes to DMEM
with 10% fetal bovine serum (catalogue numbers 31885-023
and 10500-064; Invitrogen) and incubating them for 10 min at
4 °C. The eyes were dissected in Ames’ medium (catalogue
number 15230-097; Invitrogen) supplementedwith 6.5g/liter
glucose. First, the sclera was carefully removed, leaving the ret-
inal pigmented epithelium attached to the eye ball. Incisions
weremade at the edge of the cornea to remove cornea, lens, and
hyaloid body. Then four equidistant, radial incisionsweremade
in the retina. The retinas were transferred, with retinal pig-
mented epithelium side down, to a nitrocellulose culturemem-
brane (catalogue number PICMORG50; Millipore, Molsheim,
France) and cultivated in Neurobasal A medium (catalogue
number 108888-022; Invitrogen) supplemented with B27 (cat-
alogue number 17504-044; Invitrogen), L-glutamine (catalogue
number 35050-061; Invitrogen), and penicillin/streptomycin
(catalogue number 15240; Invitrogen). Explants were main-
tained at 37 °C in a humidified 5% CO2 atmosphere. Specific
gene silencing with lentiviruses that carried a shRNA sequence
for Bbs12, Perk, Hri (catalogue numbers sc-108080 (Ctl),
sc-141483-V (Bbs12), sc-36214-V (Perk), and sc-39053-V (Hri);
SantaCruzBiotechnology, TebuBio, Yvelines, France)was per-
formed by adding 20 l of a viral suspension containing 105
infectious units to the culture medium overnight. The infected
explantswere thenwashed and cultured for 3 days, with half the
medium refreshed daily. Explants were not maintained longer
in culture to avoid unspecific apoptosis in the different retinal
layers. For pharmacological treatments, 2 mM valproic acid
(VPA dissolved in ethanol 100%; catalogue number 4543; Sig-
ma-Aldrich), 25 M guanabenz (GBZ dissolved in Me2SO; cat-
alogue number 0889; Tocris Bioscience, Ellisville, MO), or 10
M Caspase12 inhibitor (named INH dissolved in Me2SO, the
synthetic peptide Z-Ala-Thr-Ala-Asp(O-methyl)-fluorom-
ethyl-ketone; catalogue number PK-CA577-1079-100; Promo-
kine, Heidelberg, Germany) were added for single treatments
and at a 10-fold dilution for combined treatments: GIV (GBZ
2.5 M 1 M INH 0.2 mM VPA) or GV (2.5 M GBZ 0.2
mM VPA). Drugs were added simultaneously with viral infec-
tion to the culture medium.
Immunofluorescence and TUNEL Assay—For immunofluo-
rescence andTUNELassays, retinal explantswere fixed directly
on membranes with 4% buffered formaldehyde for 1 h at 4 °C.
Sucrose was then impregnated by incubating for 20min each in
10, 20, and 30% sucrose solutions. Explants were transferred to
OCT-containing molds (catalogue number 4583; Tissue-Tek,
Sakura, Villeneuve d’Ascq, France) and frozen in liquid nitro-
gen. Eight micrometer-thin cryosections were mounted on
StarFrost slides (catalogue number VS1117; Waldemar Knittel
Glasbearbeitungs, Braunschweig, Germany). Sections or cells
were washed with 1 PBS, fixed for 5 min in 4% formaldehyde
solution, and washed three times with 1 PBS. The sections
were preincubated in Teng-T (10 mM Tris-HCl, pH 7.6, 5 mM
EDTA (catalogue number E5768; Sigma-Aldrich), 150 mM
NaCl, 0.25% gelatin (catalogue numberG9391; Sigma-Aldrich),
0.05% Tween 20), and 10% normal goat serum (catalogue num-
ber PCN5000; Invitrogen)) for 30min, followed by an overnight
incubation with the primary antibody diluted in PBS with 5%
BSA at 4 °C. The slides were then washed with 1 PBS and
incubated with the indicated secondary antibody in PBS with
5% BSA for 1 h at room temperature. After washing in 1 PBS,
nuclear staining was performed with DAPI (catalogue number
D1306; Invitrogen). The slides were mounted with Immu-
mount (catalogue number 9990402; ThermoFisher). The anti-
bodies are listed in the supplemental text. The TUNEL assays
were performed using an in situ cell death detection kit (cata-
logue number 11684795910; RocheApplied Science) according
to the supplier’s protocol. The prevalence of apoptotic nuclei
was expressed as the ratio of TUNEL-positive nuclei andDAPI-
stained nuclei in three different areas of the ONL per experi-
ment. All results shown are representative of at least three sep-
arate experiments.
Light Adaptation Experiments—Light adaptation was tested
at 37 °C on explants after 3 days of culture to allow gene knock-
down. For dark to light transition experiments, the explants
were dark-adapted for 4 h and then exposed to 200 lux for 30
min by light-emitting diodes. For light to dark transition
experiments, the explants were exposed to 200 lux for 15min
before dark adaptation for 45 min. After treatment, the
explants were fixed with 4% formaldehyde in the illumina-
tion condition used.
Bbs12/ Mice Breeding and Pharmacological Treatments—
The constitutive knock-out of Bbs12 was performed to gener-
ated Bbs12/ mice, as described elsewhere (60). Bbs12/
mice were obtained by crossing heterozygous animals. The
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mice were housed in humidity- and temperature-controlled
rooms on a 12-h light/12-h dark cycle with food and water ad
libitum. For systemic VPA or systemic GBZ administration, the
drug was added to the drinking water at a concentration of 5
mg/mland50M, respectively. ForGIV in vivo (GIVin) treatment,
the animals were treated, in addition to the daily systemic admin-
istration of VPA, with eyedrops containing 7.5 M GBZ and 500
MCaspase12 inhibitor for the left eye and5%Me2SOfor the right
eye. Eyedrop treatment was given between 2 and 4 weeks of age,
andsystemic treatmentwasgivenbetween3and4weeksof age.At
4 weeks of age, electrophysiological analyses were performed, and
the retinas were harvested for molecular analysis.
Electroretinograms—The mice were dark adapted for 12 h
prior to recording. The experimentswere carried out in dim red
light (catalogue number R125IRR; Philips, Suresnes, France).
The mice were anesthetized by injecting them with 25 l/10 g
of body weight of amix containing 100l of Domitor (Domitor
1mg/ml; Janssen-Cilag, Issy-les-Moulineaux, France), 314l of
Ketamine (Ketamine 1000; Virbac, Carros, France), and 4ml of
0.9%NaCl. The pupilswere dilatedwith 0.3% atropine eyedrops
(Atropine Alcon 0.3%; Alcon, Rueil-Malmaison, France). The
animals were placed on a heating pad and kept at 37 °C during
the procedure. The reference electrode was placed under the
head skin, and the background electrode was inserted into
the tail of the animal. The measuring electrode was placed on
the cornea. To optimize contact between the cornea and the
gold electrode, a drop of methylcellulose gel (Ocry-gel; TVM
Laboratories, Lempdes, France) was added. Flashes were
delivered though a Ganzfeld lamp equipped with light-emit-
ted diodes with a maximum output of 318 cd/m2 (Siem Bio-
médicale, Nimes, France). For the scotopic electroretino-
grams, the flash duration varied from 3 to 5 ms, with the final
flash output ranging from 0.001 to 1 cd*s/m2. Responses
were amplified, filtered (1–300-Hz band pass), and digitized
(Visiosystem; Siem Biomédicale). The a and b waves were
measured by using a 1–75-Hz band pass to filter oscillatory
potentials.
RESULTS
Bbs12 Depletion in Retinal Explants Leads to Photoreceptor
Abnormalities and Impaired ICT—To investigate the impact of
Bbs12 deprivation in the photoreceptors, we developed an ex
vivo organotypic model of retinal explants that maintained ret-
inal organization and photoreceptors integrity (supplemental
Fig. S1) (23). Bbs12 shRNA-mediated depletion resulted in a
significant reduction of Bbs12 mRNA expression levels (Fig.
1A) and an even stronger reduction in BBS12 protein content in
the treated retinal explants (Fig. 1B). Subsequent histological
studies showed general disorganization of photoreceptors
(Fig. 1C) and dilatation of disks in the OS of the photorecep-
tors (Fig. 1D). ICT defects were also detected because we
could observe Rhodopsin accumulation in the IS and the
absence of Arrestin transport in the OS upon photonic stim-
ulation (Fig. 1, E and F).
Apoptotic Phenotype andMechanism in Bbs12-deprived Ret-
inal Explants—To assess photoreceptor cell death after Bbs12
inactivation, TUNEL assays were performed. A significant
3-fold increase in the number of apoptotic cells in the ONL of
Bbs12 shRNA-treated retinal explantswas counted (Fig. 2A and
supplemental Fig. S2). Measurement of the expression levels of
the different Caspases mRNAs revealed significant up-regula-
tion of the effector Caspase3, -6 and -7 (24) (Fig. 2B). The
expression level of the Caspase9 activator, which is usually acti-
vated by amitochondrial defect (25), remainedunchanged, sug-
gesting nomitochondrial involvement in the retinal phenotype
of BBS. On the other hand, the expression level of activator
Caspase12, which is activated by ER stress (26), was 2-fold
higher in Bbs12-depleted explants.
As anticipated (27), the expression the ER chaperone BiP
increased after knockdown of Bbs12 (Fig. 2B). The ER-stress
also induced ER-resident proteins IRE1 (inositol-requiring pro-
tein-1) and PERK (protein kinase RNA-like ER kinase, an ER-
resident transmembrane kinase) activation. Both IRE1 and
PERK act as sensors in the ER lumen and transmit information
to the rest of the cell (28). Active IRE1 produces an alternative,
shorter splice variant of the X-box-binding protein 1 (Xbp1)
(29). The abundance of short Xbp1 was indeed increased in
the absence of BBS12 (Fig. 2C). Activation of PERK upon
BBS12 deprivation was deduced from the increased phos-
phorylation of the eukaryotic initiation factor 2 (peIF2)
(30) (Fig. 2D). peIF2 inhibits CAP-dependent translation
and, thus, decreases cellular protein load. peIF2 also
increased the expression of Chop10 (Fig. 2B) and increased
the protein content of both BiP and CHOP10 (c/EBP-homol-
ogous protein 10; Fig. 2D and supplemental Fig. S2) in Bbs12-
deprived retinal explants.
Together with PERK, three other stress kinases are able to
phosphorylate eIF2, namely heme-regulated inhibitor, PKR
(double-stranded RNA-dependent protein kinase), and GCN2
(general control nonrepressed-2). GCN2 is activated in amino
acid starvation and UV damage conditions (31), heme-regu-
lated inhibitor during oxidative stress and heme deprivation
(32), and PKR by viral infection (33). With the same viral anti-
sense titers and culture conditions, we excluded a role for either
PKR or GCN2 in the observed phenotype. Heme-regulated
inhibitor kinase activity was excluded because simultaneous
knockdown of Bbs12 andHri had no effect on the expression
levels of the tested apoptotic genes nor altered the number of
apoptotic nuclei in the corresponding retinal explants (sup-
plemental Fig. S3). To verify that only PERK phosphorylated
eIF2 in our experiments, we performed shRNA-mediated
Perk knockdown in retinal explants (supplemental Fig. S4A)
and show that it had no effect on the expression of the tested
genes and number of apoptotic nuclei (Fig. 2, E and F). The
simultaneous depletion of Perk and Bbs12 caused, on the
other hand, a significant reduction of the number of apopto-
tic nuclei in the ONL (Fig. 2E and supplemental Fig. S4B) and
expression levels of Caspase12, Chop10, and Bip mRNAs
(Fig. 2F).
Apoptosis of Photoreceptors Is Alleviated by Targeted Phar-
macologicalModulation of KeyUPRComponents—Modulating
the activity of key UPR-related proteins protects against apo-
ptosis (22, 34). Based on our findings, BiP, PERK-mediated
phosphorylation of eIF2 and Caspase12 are key UPR actors in
Bbs12-deprived photoreceptors phenotype. We therefore tried
to modulate their activities to protect the Bbs12-depleted pho-
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toreceptors with the use of three different compounds. Up-reg-
ulation of BiP was achieved by treating the explants with valp-
roic acid (VPA) (35). Guanabenz (GBZ), an inhibitor of the
eIF2 phosphatase GADD34, was used to maintain high levels
of peIF2 and block CAP-dependent translation (36). Lastly,
Caspase12 activity was repressed by treating the photorecep-
tors with a cell-permeable synthetic peptide (INH) that specif-
ically blocks the catalytical site of the protease. In the absence of
BBS12, 36, 18, 14, and 26% of the ONL nuclei in, respectively,
untreated and VPA-, GBZ-, and INH-treated explants were
apoptotic (Fig. 3A). Interestingly, the combination of VPA,
GBZ, and INH in the GIV treatment was more efficient in
decreasing apoptosis than any of the individual components of
this combination at a 10-fold higher concentration. Indeed, the
impact of Bbs12 inactivation was completely balanced by the
simultaneous pharmacological modulation of all three targets
(Fig. 3A and supplemental Figs. S5 and S6). To understand
how GIV could be the most efficient treatment in preventing
photoreceptors apoptosis, we analyzed the level of targeted
proteins (Fig. 3B and supplemental Fig. S7). VPAandGIV treat-
ments maintained high BiP expression level in Ctl and BBS12-
deprived retinas (Fig. 3C) and specifically in photoreceptors as
validated by immunofluorescence (supplemental Fig. S8). GBZ
and GIV caused an increase in the peIF2 levels, whereas VPA
FIGURE 1. Bbs12 depletion in retinal explants induces photoreceptor abnormalities. A, Bbs12 expression levels in indicated shRNA-treated explants 72 h
after infection (n  3). shCtl, control shRNA; shBbs12, Bbs12-shRNA. *, p  0.01. B, immunodetection of BBS12 and -tubulin as loading control in treated
explants. C, toluidin blue-stained sections of treated explants. Scale bars, 50 m. INL, inner nuclear layer. D, transmission electron microscopy (TEM) pictures
showing photoreceptors OS and connecting cilium (CC) of shCtl-treated (upper panel) and shBbs12-treated (lower panel) explants. Scale bars, 500 nm. E,
immunostaining of Rhodopsin with DAPI and OS counterstaining using Agglutinin in treated explants. Scale bars, 15 m. F, immunostaining of Arrestin in
dark-adapted (left panel) and in light-adapted (right panel) treated explants and schematic representation shows the expected localization of Arrestin under
both conditions. Scale bars, 15 m. See supplemental Fig. S1C for OS and ONL staining.
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decreased it (Fig. 3D). A significant increase of CHOP10 pro-
tein levels was observed by GBZ and GIV treatment. As
expected, VPA decreased the concentration of CHOP10 (Fig.
3E). Surprisingly, the impact of INH on apoptosis correlated
with a decrease in peIF2 and CHOP10. On the other hand,
GIV treatment was the only treatment that successfully
increased simultaneously BiP, peIF2, and CHOP10 concen-
trations (Fig. 3, C–E). We next established that these GIV-me-
FIGURE 2. Bbs12 depleted retinal explants present ER stress-mediated apoptosis. A, TUNEL assays on indicated treated explants, 72 h after infection;
apoptotic nuclei labeled in green and DAPI counterstaining. Scale bars, 25 m. See supplemental Fig. S2A for corresponding apoptotic levels. B, expression
analysis of Caspase3, -6, -7, -9, -12, Bip, and Chop10 in treated explants (n  3). *, p  0.01. C, reverse transcription PCR of both long (unstressed) and short
(unfolded protein response-related) forms of Xbp1. D, immunodetection of peIF2, eIF2tot, BiP, and CHOP10 in the indicated shRNA-treated explants. See
supplemental Fig. S2 (B–D), for loading controls and quantification. E, TUNEL assays in shCtl, shBbs12, shPerk, or shBbs12 shPerk-treated explants. Scale bars,
25 m. See supplemental Fig. S4 for corresponding apoptotic levels and Perk knockdown validation. F, expression analysis of Caspase12, Bip, and Chop10 in
indicated shRNA-treated explants (n 3). **, p 0.05.
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diated protective effects were based on the synergistic action of
all three compounds. The combination of GBZ and VPA (GV)
did not increase all three targets and was therefore less protec-
tive against apoptosis (18% apoptotic nuclei for GV versus 13%
for GIV; Fig. 3F and supplemental Fig. S9).
Retinal Phenotype of Bbs12/Mice—Histological studies in
4-week-old mice revealed a thinning of the retinal cell layers in
Bbs12/mice (Fig. 4A) as exemplified by the measurement of
the ONL (37 m in Bbs12/ retinas compared with 65 m in
Bbs12/ retinas; Fig. 4B) and the drastic thinning of IS andOS.
Transmission electron microscopy showed dilatation of disks
inside the disrupted OS (Fig. 4C). Scotopic electroretinogram
(ERG) recordings of these mice revealed a significant general
decrease in the response to light stimuli, primarily linked to a sub-
stantial loss of the a-wave in Bbs12/mice (Fig. 4D, red arrows).
The characteristic localization of Rhodopsin and Arrestin to the
OS was lost in the Bbs12/mice (Fig. 4, E and F), which implies
severe ICT defects in the Bbs12/ retina. Finally, the massive
accumulation of proteins in the IS resulted in swelling of the ER
cisternae of the Bbs12/ photoreceptors (Fig. 4G).
FIGURE 3.Pharmacologicalmodulation ofUPR-related actors reduces apoptosis inBbs12-depleted retinal explants.A, effect on apoptotic levels of VPA
or GBZ or INH or GIV treatments on shCtl and shBbs12 explants (counted as TUNEL positive nuclei/DAPI in the ONL, n 3). *, p 0.01. See supplemental Figs.
S5A and S6 for TUNEL assay. B, immunodetection of peIF2, eIF2tot, CHOP10, and BiP in the indicated shRNA-treated explants. See supplemental Fig. S7 for
loadingcontrols.C–E, quantificationofpeIF2/tot,CHOP10, andBiP levels in the indicatedshRNA-treatedexplants (n3). **,p0.05.F, table summarizing theeffect
of the different treatments on targeted proteins and apoptosis level (% S.E.). See supplemental Fig. S9 for VPA 0.2mMGBZ 2.5M treated explants.
UPRModulation Reduces BBS-induced Retinal Apoptosis
37488 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 44•OCTOBER 26, 2012
 at U










Kinetics of Apoptosis in the Bbs12/ Retina—Retinal
degeneration was well underway by 4 weeks postnatally. By
studying the developmental changes in the abundance apo-
ptotic nuclei in Bbs12/ and Bbs12/ mice, we observed
the first BBS12-dependent increase in cell death between
postnatal days 12 and 14 (Fig. 5A). Furthermore, expression
of Caspase3, Caspase6, Caspase12, Bip, and Chop10mRNAs
was significantly up-regulated in Bbs12/ retinas at post-
natal day 14 (Fig. 5B), which correlated with an increase of
BiP and CHOP10 protein contents in the Bbs12/ retinas
(Fig. 5C and supplemental Fig. S10). These data validate the
ex vivo findings that ER stress is activated in BBS12-deprived
retinas.
In Vivo Pharmacological Modulation of the UPR Slows Pho-
toreceptor Loss Preserves Light Detection in Bbs12/ Retinas—
We next tried to protect Bbs12/ retinas in vivo against apo-
ptosis. Systemic treatment with VPA or GBZ in the drinking
water did indeed have a positive effect on the retinal phenotype
of theBbs12/mice, because both systemicVPA and systemic
GBZ administration mediated a thickening of the ONL (sup-
plemental Fig. S12, A and B). Both treatments yielded an
improvement of the light-detecting capacity of the photorecep-
tors, with an increased magnitude of the a-wave on ERG
recordings (supplemental Fig. S12D). Interestingly, systemic
VPA did not cause significant hepatic dysfunction in treated
mice, as demonstrated by urea concentration in plasma,
FIGURE 4. Bbs12/mouse presents retinal degeneration. A, toluidin blue-stained sections of theWT (Bbs12/, left panel) and KO (Bbs12/, right panel)
retinas at 4 weeks of age. Scale bars, 50 M. B, determination of ONL thickness of theWT and KOmice at 4 weeks (n 6). *, p 0.01. C, transmission electron
microscopy (TEM) pictures of the outer segments of WT and KO retinas at 4 weeks. Scale bars, 1M. Arrows point to disk dilatation.D, scotopic ERG recordings
for specified genotypes at 4 weeks. Red arrows present a-waves. E and F, immunostaining of Rhodopsin (E, Rho) and Arrestin (Arr, F) inWT and KO retinas at 4
weeks with DAPI and OS counterstaining using Agglutinin (Agg). Scale bars, 20 m. G, transmission electron microscopy analysis of inner segments with ER
cisternae encircled in red at 4 weeks of age. Scale bars, 200 nM. INL, inner nuclear layer.
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whereas systemic GBZ significantly did (supplemental Fig.
S13). We therefore retained systemic administration for VPA
but used a local eyedrop administration approach for bothGBZ
and the INH for our GIVin treatment. The INH oligopeptide
cannot be administered orally. Furthermore, we did not try to
inject the compounds because we did not want to risk an unex-
pected phenotype because of their antiapoptotic activity. GIVin
treatment was able to protect the retina of Bbs12/mice sub-
stantially: the thickness of the ONL layer increased from 33
m in untreated Bbs12/ animals to 54 m in GIVin-
treated Bbs12/ ones (Fig. 6, A and B). As in our ex vivo
condition, GIVin increased the tissue concentration of BiP,
peIF2, and CHOP10 in Bbs12/-treated animals (Fig. 6C
and supplemental Fig. S11). In addition, Rhodopsin protein
FIGURE 5. Apoptosis in Bbs12/ retina. A, TUNEL assays inWT and KO retinas at postnatal days (PN) 10, 12, and 14. Scale bars, 30 m. B, expression analysis
of Caspase3, -6, -7, and -12, Bip, and Chop10 inWT and KO retinas (n 3). *, p 0.05). C, immunodetection of BiP peIF2, eIF2tot, and CHOP10 in 2-week-old
WT and KO retinas. See supplemental Fig. S10 for loading controls.
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levels were decreased upon GIVin treatment, independently
of the treated genotype (Fig. 6C and supplemental Fig. S11).
This GIVin-mediated improvement of retinal thickness in
the Bbs12 KO corresponded with preservation of the ampli-
tudes of a- and b-waves on ERGs (Fig. 6D). Indeed, we
observed a2.7-fold increase in the amplitude of the a-wave
(Fig. 6E) and a 1.5-fold increase in that of the b-wave (Fig.
6F).
FIGURE 6. Pharmacological modulation of UPR prevents photoreceptors loss in Bbs12/ retina. A, immunostaining of acetylated -tubulin with DAPI
counterstaining in indicated treated animals at 4 weeks of age. Scale bars, 20M. B, comparison of ONL length of GIVin treated and untreatedmice at 4 weeks
of age (n 6). *, p 0.01. C, immunodetection of BiP, peIF2, eIF2tot, CHOP10, and Rhodopsin in retinas from indicated treated 4-week-old animals. See
supplemental Fig. S11 for loading controls andquantification.D, scotopic ERG recordings of animalswith indicated treatment andgenotype at 4weeks of age.
E, scotopic a-wave amplitude versus stimulus intensity (log) function of animals with indicated treatment and genotype at 4 weeks of age (n 12). *, p 0.05.
F, scotopicb-wave amplitude versus stimulus intensity (log) functionof indicated animals (n12). **,p0.05. The animalswere treated for 2weekswithGIVin:
topical GBZ 7,5 M topical INH 500 M systemic VPA 5 mg/ml.
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BBS is a ciliopathy characterizedby anearly onset ofRPbecause
of photoreceptor apoptosis. However, the precise cellular mecha-
nisms leading to cell death are not known. Recently, tauroursode-
oxycholic acidwas reported tohavebeneficial effectson the retinal
phenotype of the Bbs1M390R/M390Rmouse (37). Tauroursodeoxy-
cholic acid was described in that study as having an antiapoptotic
effect inducing retinal thickening in treated animals, but its exact
apoptotic mechanism has so far remain undetermined. In this
study, we integrated ex vivo and in vivo approaches to dissect the
mechanism involved in retinal degeneration in the absence of one
of theBBSmembers,namelyBBS12.The latter impaired theciliary
trafficking of key photoreceptor proteins and caused photorecep-
tor cell death through prolonged UPR activation. Based on these
findings, we defined theGIVin treatment, which resulted in a sub-
stantial protection of the photoreceptors against apoptosis and
maintained the ability to detect light in vivo.
PERK-mediated Branch of the UPR Drives Apoptosis in
BBS12-deprived Photoreceptors—This protein overload in the
IS induced an accumulation of proteins inside the ER lumen, as
reflected by the characteristic swelling of the ER cisternae (Fig.
4G). An unbalance between the amounts of de novo synthesized
proteins and the amount of the BiP chaperone residing in the
ER causes ER stress and activates the UPR pathway. In the
BBS12-deprived photoreceptors, the UPRwas characterized by
increased BiP, Caspase12, and peIF2 tissue levels. The three
main cellular stress transducers (IRE1, PERK, and ATF6 (15))
have different temporal patterns of activation during the UPR
signaling cascade (20). IRE1 was activated in absence of BBS12,
because we could detect the stress-induced splice variant of
Xbp1. Nevertheless, this branch was not selected as a pharma-
cological target because it does not induce apoptosis during ER
stress but instead regulates lipogenesis and ER-associated pro-
tein degradation (38). The transcription factor ATF6 regulates
the expression of UPR genes, such as BiP, to increase ER folding
capacity and expression of ER-associated protein degradation
genes to ameliorate protein overload (39) but is not involved in
cell death (40). The PERK-dependent branch of theUPR, on the
other hand, is proapoptotic for cells submitted to pertinacious
ER stress (41). Our results confirmed that PERK activity was
required to launch the apoptotic cascade in the absence of
BBS12 and highlight that the PERK branch is the UPR branch
that drives apoptosis in BBS12-depleted photoreceptors.
Efficient Decrease of Overall Cellular Protein Load in BBS12-
deprived Photoreceptors Protects against Apoptosis and Preserved
LightDetection—Withprolongedproteinoverload leading to apo-
ptosis of the BBS12-deprived photoreceptors, decreasing protein
load by either degrading the newly synthesized proteins or pre-
venting their biosynthesis represents interesting therapeutic ave-
nues. In this respect, VPA is known tomodulate transcription and
activity of BiP, a resident ER chaperone (35), and is already being
used as a neuroprotective agent in retinal diseases (42). VPA pro-
tects, for example, retinal cells in the rat against apoptosis that is
induced by ischemia-reperfusion injury by increasing BiP expres-
sion and reducing Caspase12 activation (43). In BBS12-deprived
retinal explants, VPA treatment induced a significant increase of
BiP protein level and reduction in apoptosis. Interestingly, Bip
mRNA level was lower in Bbs12-depleted explants treated with
VPA than in Bbs12-depleted retinal explants without VPA treat-
ment, although this level was higher than the shCtl explants with-
out pharmacological treatment. This is probably correlated with
the known uncorrelated rates between Bip transcription and
translation (44). Consistent with the fact that increasing the BiP/
nascent proteins ratio in the ER favored unfolded proteins degra-
dation, hence decreasing overall cellular protein load (45), mice
treatedwithVPAalone (supplementalFig. S12C) showeddecrease
Rhodopsin protein content. This effect was associated with
increased ONL thickness and improved ERG recordings (supple-
mental Fig. S12,B andD). Apart from being a historical drug used
to treat epilepsy in human patients (46), VPAwas recently used in
a trial of retinitis pigmentosa patients with mutations in the Rho-
dopsin gene (47–49). AlthoughVPA-treated patients had a larger
visual field than untreated patients in the first study, controversy
arose because of inefficiency for other patients and a lack ofmech-
anistic insight on how the VPA protected against apoptosis. Our
results contribute to clarifying the underlying mechanism of the
beneficial outcome observed in a subset of RP patients.
The second approach to prevent deleterious protein over-
load is to maintain high levels of peIF2, thereby inhibiting
CAP-dependent translation (50). We opted to inhibit the
dephosphorylation of peIF2 using GBZ, a specific inhibitor of
the eIF2-phosphatase, GADD34 (36). GBZ bears anti-prion
activity (34) and was used to cure diseases linked to unfolded
proteins conditions (51). Efficacy in reducing protein load in
the photoreceptor was successfully demonstrated in the
Ahi1/ mouse (14). Loss of the ciliary protein AHI1 causes
retinitis pigmentosa in mice and retinal degeneration in
humans suffering from some variants of Joubert syndrome,
another ciliopathy. In our studies, GBZ specifically increased
peIF2 andCHOP10 protein levels. CHOP10 is associatedwith
both pro- and antiapoptotic activities (52, 53), but our study
demonstrates that GBZ-mediated CHOP10 increase is mainly
antiapoptotic in BBS-deprived photoreceptors.Moreover, as for
VPA, the beneficial effect of GBZ was associated with decreased
protein load as demonstrated by the significant reduction of Rho-
dopsinprotein levels (supplemental Figs. S12CandS14).There is a
reduced Rhodopsin load that is presumably in good shape and
correctly located in the treated mice, whereas in untreated mice,
Rhodopsin is aggregated in the IS andnot functional. In aggregate,
these findingsclearlydemonstrate that it is aproteinaccumulation
inside the ISof theBBS-deficientphotoreceptors that triggers apo-
ptosis and that pharmacological reductionof this protein overload
has a major beneficial effect.
Simultaneous Increase of ER-resident Chaperone BiP Activ-
ity, Inhibition of CAP-dependent Translation, and Inactivation
of Caspase12 Activity Represent the Most Efficient Way to
Maintain Photoreceptors—Although substantial protection
was obtained against apoptosis with either VPA orGBZ or both
(supplemental Fig. S8), there was still a significant increase in
apoptotic nuclei in absence of BBS12 in these treated photore-
ceptors. Even though we could measure a substantial decrease
in Rhodopsin, themost abundant photoreceptor protein, in the
treated BBS12-deperived photoreceptors, the maintained sig-
nificant apoptotic activity indicated residual UPR activation. In
an attempt to optimize our protective treatment, we tested a
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third pharmacological approach based on the UPR-specific
Caspase12 inhibition (54, 55). Used alone, the Caspase12 inhib-
itor INH was 20% less efficient in preventing apoptosis than
VPA or GBZ (Fig. 3), even if it unexpectedly impacted the
peIF2 and CHOP10 levels but not BiP expression levels. Inter-
estingly, GIV, combining the three molecules, was the most effi-
cientway todecrease apoptotic levels both ex vivo and in vivo. This
result could be associatedwith the synergistic up-regulation of the
three targets, namely BiP, peIF2, and CHO10 (Fig. 3F).
GIV Treatment, Other BBS Proteins, and Time of Admin-
istration—In this study, we showed that the efficient modula-
tion of the UPR induced by a defect in ICT in BBS12-deprived
photoreceptors allows successful slow down of photoreceptor
apoptosis. Our finding is strengthened by the previously used
tauroursodeoxycholic acid treatment in the Bbs1mutatedmice
because it is a detergent and chemical chaperone that enhances
the adaptive capacity of the ER in UPR conditions (56, 57).
These results demonstrate that the proapoptotic mechanism is
similar in both cases and thatGIV canmost probably be extrap-
olated to all known BBS proteins as they all interact together
(58). Interestingly, the first detectable apoptotic responses
developed between postnatal days 12 and 14, that is, when pho-
toreceptors have differentiated and matured (59). These data
therefore indicate that BBS12 protein is not required for the
maturation process of the photoreceptors but becomes essen-
tial for photoreceptor function.We show that pharmacological
treatment can therefore be administered once the photorecep-
tors are functionally detecting light stimulus.
Conclusion—The identification of the precise UPR mecha-
nism and the optimized GIV treatment represent an efficient
strategy in preserving vision in the studied model with possible
extension to patients. This pharmacological treatment could
potentially be extended to the other ciliopathies, once proven
that they share similar UPR proapoptotic mechanisms. How-
ever, thispharmacological treatment shouldnotbeconsideredasa
long term curative treatment such as gene therapy. In fact, both
techniques are complementary, because the pharmacological
approach aims to preserve themaximumnumber of healthy pho-
toreceptor cells preparing for gene therapy. Pharmacological
dynamics, toxicity studies, and applicability to human beings are
the next steps following this work pointing to precise targets for
preventing retinal degeneration in ciliopathies.
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